Workplace Migraine Treatment | Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?
Workplace Migraine Treatment research study
What is the primary objective of this study?
Researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with Treximet. During this research subjects will take Treximet to treat 3 workday migraine attacks. For a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. The subjects will complete questionnaires after treating each migraine.
Who is eligible to participate?
Inclusion Criteria: - episodic migraine diagnosis - age 18 or older - currently using a triptan as primary migraine monotherapy - currently employed - if of childbearing potential, willing to prevent pregnancy during study participation - able to understand and consent to study participation Exclusion Criteria: - younger than age 18 - not having episodic migraine diagnosis - not using a triptan as primary migraine monotherapy - not currently employed - pregnant or nursing or unwilling to prevent pregnancy during study participation - unable to understand and consent to study participation
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Workplace Migraine Treatment
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:TriptanUsual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
Drug:Treximet 85Mg-500Mg TabletTreximet is 85 mg sumatriptan plus 500 mg naproxen sodium
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
TriptanArm 1 subjects began with their prescribed triptan
Treximet 85Mg-500Mg TabletArm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
Start Date: September 2009
Completed Date: August 2016
Phase: Phase 4
Primary Outcome: Workplace Productivity and Activity Impairment Scale (WPAI).
Secondary Outcome: Lost Workplace Productivity
Study sponsors, principal investigator, and references
Principal Investigator: Jennifer S Kriegler, MD
Lead Sponsor: The Cleveland Clinic
Mathew NT, Landy S, Stark S, Tietjen GE, Derosier FJ, White J, Lener SE, Bukenya D. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009 Jul;49(7):971-82. doi: 10.1111/j.1526-4610.2009.01458.x. Epub 2009 May 27.